Nasdaq: AUPH Symbol. Price. Change. Volume. Day Range. 52 Wk Range. Company Overview. Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need.

Changing the course of autoimmune disease. Aurinia exists to make a difference. Our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease.

share. save. hide. report. 95% Upvoted. Log in or sign up to leave a comment Log In Sign Up. Sort by.

Reply. 2 0. Report. Saurabh Kumar Jan 23, 2021 12:10PM ET. AUPH Aurinia Pharmaceuticals $12.67 / -0.175 (-1.36%). 03/15/21 Aurinia Pharma reports positive cost-effectiveness assessment of LUPKYNIS 01/24/21 FDA approves Aurinia's LUPKYNIS for adult patients with active lupus nephritis View the real-time AUPH price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Aurinia Pharmaceuticals against related stocks people have also bought.

Royal Bank of Canada is very positive to AUPH and gave it a "Outperform" rating on February 25, 2021. The price target was set to $28.00 → $26.00. Over the last …

% of Funds with AUPH in top 20 holdings: 0.65% % of shares outstanding owned by hedge funds: NA % change in shares owned since previous qtr:-32.41%: Total # of shares held by hedge funds: 21462900: Total value of shares held by hedge funds: $296833000: Average rank of AUPH in portfolios: 514: Aggregate Ownership History by hedge funds: Royal Bank of Canada is very positive to AUPH and gave it a "Outperform" rating on February 25, 2021. The price target was set to $28.00 → $26.00. Over the last 30 days, this security got 1 buy, 0 sell, and 0 hold ratings.

Find the latest Aurinia Pharmaceuticals Inc (AUPH) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) on Thursday, setting a price target of … 2019-12-11 Aurinia Pharmaceuticals Buyout. Aurinia (AUPH) is past the most challenging part after their late-stage trial for the experimental lupus nephritis drug candidate, voclosporin, were positive. The news lifted the stock 125% in a day when the news broke. Seeking Alpha - On January 22, the FDA approved Aurinia Pharmaceuticals' Voclosporin to treat Lupus Nephritis, making Aurinia a prime target for some great Pharma in … AUPH spent the summer as a bummer for all who bought the secondary at $15, but fall conferences ( OPCO on SEPT 23) will get the bystanders in this jewel which should eventually be bought out. $40 BUYOUT THIS WEEKEND? wouldn't be unreasonable.

The news lifted the stock 125% in a day when the news broke. Seeking Alpha - On January 22, the FDA approved Aurinia Pharmaceuticals' Voclosporin to treat Lupus Nephritis, making Aurinia a prime target for some great Pharma in … AUPH spent the summer as a bummer for all who bought the secondary at $15, but fall conferences ( OPCO on SEPT 23) will get the bystanders in this jewel which should eventually be bought out. $40 BUYOUT THIS WEEKEND? wouldn't be unreasonable.
Black bar stools

AUPH is above the last capital raise $15 and target is $21!! AUPH, 1D. Long. Trade4158.

For example, this November Motley Fool article assumed a weaker, somewhat needy AUPH.
Abonnemang till surfplattan

försvarsmakten jobb test
skolskjuts västerås
inbetalning moms 2021
it konsult luleå
apoteket flygstaden
äta griskött rosa

Changing the course of autoimmune disease. Aurinia exists to make a difference. Our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease.

Aurinia (AUPH) is past the most challenging part after their late-stage trial for the experimental lupus nephritis drug candidate, voclosporin, were positive. The news lifted the stock 125% in a day when the news broke. Seeking Alpha - On January 22, the FDA approved Aurinia Pharmaceuticals' Voclosporin to treat Lupus Nephritis, making Aurinia a prime target for some great Pharma in … AUPH spent the summer as a bummer for all who bought the secondary at $15, but fall conferences ( OPCO on SEPT 23) will get the bystanders in this jewel which should eventually be bought out.

Cv forkortning
traditionellt svenskt bröllop

Aurinia Pharmaceuticals AUPH potential buyout:Upped the Ante Aurinia ( AUPH) Looks Good: Stock Adds 5.5% in Session. Aurinia Pharmaceuticals:

I was accused of pumping AUPH when Yahoo Admin M shorted it at $3.52 on 10/10/2019. I don't sell but add more when it pulls back. Aurinia Pharmaceuticals, A Great Candidate For A Potential Buyout Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings Changing the course of autoimmune disease. We are committed to transforming people’s lives by delivering therapeutics that change the course of autoimmune disease. I was accused of pumping AUPH when Yahoo Admin M shorted it at $3.52 on 10/10/2019. I don't sell but add more when it pulls back. Aurinia Pharmaceuticals, A Great Candidate For A Potential Buyout In 2021 - … However, when recommending AUPH, Bernardino gains 48.8% in average profits on the stock.